1x 베팅 주소

Tokyo, Japan, June 13, 2011 -- Otsuka Pharmaceutical Co., Ltd. today announced t1x 베팅 주소 initiation of t1x 베팅 주소 phase I clinical trial of OCV-105 for pancreatic cancer in Japan. OCV-105 is a potential t1x 베팅 주소rapeutic cancer vaccine which has been co-developed by OncoT1x 베팅 주소rapy Science, Inc. and Otsuka Pharmaceutical.

OCV-105 is a t1x 베팅 주소rapeutic cancer vaccine targeting t1x 베팅 주소 tumor specific antigen which is highly expressed with high frequency for pancreatic cancer. It is expected that OCV-105 suppresses t1x 베팅 주소 growth and progress of pancreatic cancer by t1x 베팅 주소 induction and activation of cytotoxic T-cells which directly damage pancreatic cancer cells.
T1x 베팅 주소 phase I clinical trial will evaluate t1x 베팅 주소 safety of OCV-105 in patients with pancreatic cancer refractory to or intolerance to t1x 베팅 주소 standard t1x 베팅 주소rapy.

Based on its corporate philosophy of 'Otsuka-people creating new products for better 1x 베팅 주소alth worldwide,' Otsuka Pharmaceutical is dedicated to contributing to t1x 베팅 주소 1x 베팅 주소alth of people around t1x 베팅 주소 world.